Abstract
Rituximab is a monoclonal antibody to CD20, often used to treat B-cell lymphomas and various autoimmune diseases. While there is extensive literature on rituximab-induced liver injury related to hepatitis B reactivation, there have been no reports to date of autoimmune-type idiopathic drug-induced liver injury from this drug. We present a case of necro-inflammatory hepatitis with autoimmune features in a 40-year-old female after receiving a second dose of rituximab for mucosa-associated lymphoid tissue (MALT) lymphoma, with a review of the literature.
| Original language | English |
|---|---|
| Pages (from-to) | 381-386 |
| Number of pages | 6 |
| Journal | Canadian Liver Journal |
| Volume | 3 |
| Issue number | 4 |
| DOIs | |
| State | Published - 1 Jan 2020 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Autoimmune hepatitis
- Drug-induced liver injury
- Idiopathic drug-induced liver injury
- MALT lymphoma
- Necro-inflammatory hepatitis
- Rituximab
ASJC Scopus subject areas
- Hepatology
Fingerprint
Dive into the research topics of 'Rituximab-induced autoimmune hepatitis: A case study and literature review'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver